Guangzhou Wondfo Forms $16 Million Diagnostics JV with Biocartis

Guangzhou Wondfo Biotech has formed a JV with Biocartis Group of Belgium to commercialize Biocartis' molecular diagnostics Idylla system in China . Wondfo provides medical diagnostic tests and testing equipment to global markets. The Idylla device is an automated, real-time Polymerase Chain Reaction (PCR) molecular diagnostics system, designed for clinical use. Biocartis and Wondfo will each own a 50% stake in the JV, which they will fund with a total of $16 million in equity. More details.... Share this with colleagues: // //